Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity



Status:Active, not recruiting
Conditions:Obesity Weight Loss
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:12 - 17
Updated:3/17/2019
Start Date:September 29, 2016
End Date:August 8, 2019

Use our guide to learn which trials are right for you!

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug

This trial is conducted globally. The aim of this trial is to investigate the effect of
liraglutide for weight management in pubertal adolescent subjects with obesity.


Inclusion Criteria:

- Informed consent obtained before any trial-related activities. Trial-related
activities are any procedures that are carried out as part of the trial, including
activities to determine suitability for the trial

- Male or female, age 12 to less than 18 years at the time of signing informed consent
and less than 18 years at date of randomisation

- BMI corresponding to equal to or above 30 kg/m^2 for adults by international cut-off
points and equal or above the 95th percentile for age and sex (for diagnosis of
obesity)

- Stable body weight during the previous 90 days before screening V2 (below 5 kg
self-reported weight change)

- History of failing to lose sufficient weight with lifestyle modification as judged by
the investigator and documented in subject's medical record

Exclusion Criteria:

- Pre-pubertal subjects (Tanner stage 1) at screening V2

- Type 1 diabetes mellitus (T1DM)

- Family or personal history of multiple endocrine neoplasia type 2 (MEN2)

- Medullary thyroid carcinoma (MTC)

- History of pancreatitis (acute or chronic)

- Subjects with secondary causes of obesity (i.e., hypothalamic, genetic or endocrine
causes)

- Treatment with medications within 90 days before screening V2 that, based on the
investigator's judgement, may cause significant weight change. This should also
include treatment with any of the following medications: pramlintide, orlistat,
zonisamide, topiramate, lorcaserin, phenteremine, bupropion, naltrexone, glucagon-like
peptide-1 (GLP-1) receptor agonists, or metformin (used as treatment for obesity)

- Anti-diabetic treatment other than metformin

- History of major depressive disorder within 2 years before screening V2
We found this trial at
12
sites
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Baltimore, Maryland 21229
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Baton Rouge, Louisiana 70808
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
?
mi
from
Brussels,
Click here to add this to my saved trials
Buffalo, New York 14222
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Charleston, South Carolina 29407
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Columbus, Ohio 43205
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Greenville, South Carolina 29607
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Memphis, Tennessee 38119
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Meridian, Idaho 83646
?
mi
from
Meridian, ID
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15224
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials